Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/105845
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKumeria, T.-
dc.contributor.authorMcInnes, S.-
dc.contributor.authorMaher, S.-
dc.contributor.authorSantos, A.-
dc.date.issued2017-
dc.identifier.citationExpert Opinion on Drug Delivery, 2017; 14(12):1407-1422-
dc.identifier.issn1742-5247-
dc.identifier.issn1744-7593-
dc.identifier.urihttp://hdl.handle.net/2440/105845-
dc.description.abstractIntroduction: Porous silicon (pSi) engineered by electrochemical etching has been used as a drug delivery vehicle to address the intrinsic limitations of traditional therapeutics. Biodegradability, biocompatibility, and optoelectronic properties make pSi a unique candidate for developing biomaterials for theranostics and photodynamic therapies. This review presents an updated overview about the recent therapeutic systems based on pSi, with a critical analysis on the problems and opportunities that this technology faces as well as highlighting pSi's growing potential. Areas covered: Recent progress in pSi-based research includes drug delivery systems, including biocompatibility studies, drug delivery, theranostics, and clinical trials with the most relevant examples of pSi-based systems presented here. A critical analysis about the technical advantages and disadvantages of these systems is provided along with an assessment on the challenges that this technology faces, including clinical trials and investors' support. Expert opinion: pSi is an outstanding material that could improve existing drug delivery and photodynamic therapies in different areas, paving the way for developing advanced theranostic nanomedicines and incorporating payloads of therapeutics with imaging capabilities. However, more extensive in-vivo studies are needed to assess the feasibility and reliability of this technology for clinical practice. The technical and commercial challenges that this technology face are still uncertain.-
dc.description.statementofresponsibilityTushar Kumeria, Steven J. P. McInnes, Shaheer Maher and Abel Santos-
dc.language.isoen-
dc.publisherTaylor & Francis-
dc.rights© 2017 Informa UK Limited, trading as Taylor & Francis Group-
dc.source.urihttp://dx.doi.org/10.1080/17425247.2017.1317245-
dc.subjectPorous silicon-
dc.subjectdrug delivery-
dc.subjectimaging-
dc.subjecttheranostics-
dc.subjecttherapy-
dc.subjecttoxicity-
dc.titlePorous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives-
dc.typeJournal article-
dc.identifier.doi10.1080/17425247.2017.1317245-
dc.relation.granthttp://purl.org/au-research/grants/arc/DE140100549-
pubs.publication-statusPublished-
dc.identifier.orcidMaher, S. [0000-0002-2556-1096]-
dc.identifier.orcidSantos, A. [0000-0002-5081-5684]-
Appears in Collections:Aurora harvest 8
Pharmacology publications

Files in This Item:
File Description SizeFormat 
hdl_105845.pdfAccepted version2.31 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.